The group now has 325 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
The product will be commercialized from Unichem's Ghaziabad plant
The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula
The company is excluding data from the affected sites to maintain the study's integrity
This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Subscribe To Our Newsletter & Stay Updated
